One-year outcomes after Amulet or Watchman/FLX device for percutaneous left atrial appendage closure: a pre-specified analysis of the SWISS-APERO randomized clinical trial

Reported from TCT 2023

Alex Sticchi interviews Roberto Galea on the 1-year results of the SWISS-APERO randomized clinical trial, which he presented at TCT Congress 2023 in San Francisco.

Among patients undergoing clinically indicated LAAC and in whom LAA anatomy was deemed suitable for both devices, rates of patency and device-related thrombus at 13-month cardiac computed tomography angiography, as well as clinical outcomes, were similar between the two groups.